Vor Biopharma (VOR) AI Stock Analysis

• Market Cap: $548.06M
• Dividend Yield: N/A
• Average Volume (3M): 790.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 4.98
• Revenue Growth: N/A
• EPS Growth: -1072.48%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -121.63
• Shares Outstanding: 41,519,840
• 10 Day Avg. Volume: 518,794
• 30 Day Avg. Volume: 790,677
• PEG Ratio: 0.23
• Price to Book (P/B): 0.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.76
• Enterprise Value/Market Cap: -0.09
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 30.60
• Enterprise Value/Ebitda: 0.05
• 1Y Price Target: $36.25
• Price Target Upside: 167.53% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $13.00 ▼(-4.06% Downside)
• Action: Reiterated Date: 01/21/26
• Date: Action: Reiterated 01/21/26

The score is held down primarily by weak financial fundamentals (no revenue, heavy cash burn, and a sharp deterioration to deeply negative equity). Offsetting this are improving near-term technical momentum and positive corporate developments (recent financings and encouraging telitacicept updates), but valuation remains constrained by ongoing losses and no dividend support.

Positive Factors

Established partner commercial footprint for telitacicept

Partnering with RemeGen gives Vor an existing commercial and clinical data foundation in China, reducing regulatory and market execution risk. Established safety and treated-patient experience materially de-risks global development, supports regulatory filings and may accelerate uptake if approvals follow.

Institutional backing and board additions

Large institutional investors taking board seats improves access to follow-on capital and strategic guidance. Their commercial and capital-markets expertise can materially improve financing options, governance and program prioritization across multi-year Phase 3 efforts.

Material cash runway to fund Phase 3 programs

Having roughly $450M in cash and investments supports execution of planned global Phase 3 trials and pre-commercial activities through mid-2028. This reduces near-term financing pressure and allows management to focus on development milestones that create long-term value.

Negative Factors

No commercial revenue

Absence of product revenue means Vor must rely on partnerships and capital markets for funding. This structure creates ongoing financing dependency and exposes the company to dilution risk and program delays if clinical outcomes or funding access deteriorate.

Deeply negative stockholders' equity

Negative equity materially weakens the balance sheet, potentially complicating future financings and limiting strategic options. It raises the likelihood of dilutive capital raises or restructuring and reduces the firm's ability to absorb setbacks without significant shareholder dilution.

Option repricing and compensation changes

Repricing indicates retention challenges and wage-pressure in a competitive talent market; it also signals potential future dilution to preserve staff. Over time this can harm shareholder alignment, increase share overhang, and suggest higher ongoing compensation costs to sustain R&D execution.

Vor Biopharma Business Overview & Revenue Model

Company Description

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Vor Biopharma generates revenue primarily through research and development collaborations, partnerships, and potential future product sales. The company's business model is centered around developing its pipeline of eHSC-based therapies, which are designed to improve the efficacy and safety of existing cancer treatments. Revenue streams may include milestone payments and royalties from strategic partnerships with larger pharmaceutical companies, as well as potential licensing agreements for its proprietary technologies. Additionally, Vor Biopharma may secure funding through government grants or research institutions to support its innovative research initiatives.

Vor Biopharma Financial Statement Overview

Summary

Development-stage profile with no revenue and persistent, heavy cash burn. Financial risk is elevated due to the sharp TTM net loss spike (~$2.45B) and stockholders’ equity turning deeply negative (about -$2.23B), which can constrain financing flexibility despite low stated debt.

Income Statement

The company reports no revenue across annual periods, which is typical for an early-stage biotech but materially limits operating leverage. Losses are large and worsening: net loss moved from about $69M (2021) / $92M (2022) / $118M (2023) / $117M (2024) to roughly $2.45B in TTM (Trailing-Twelve-Months), signaling a major step-up in charges or spending. Profitability is deeply negative in TTM (Trailing-Twelve-Months) with substantial operating losses, and the margin profile is not yet trending toward breakeven.

Balance Sheet

Leverage is low in absolute terms in TTM (Trailing-Twelve-Months) (total debt roughly $3.1M), but the capital structure has weakened sharply: stockholders’ equity flipped from positive ($96.7M in 2024) to deeply negative in TTM (Trailing-Twelve-Months) (about -$2.23B). Total assets are down versus earlier years (about $176M TTM vs. ~$299M in 2022), pointing to balance sheet contraction. Negative equity is a key risk factor and reduces financial flexibility even if stated debt is modest.

Cash Flow

Cash burn remains heavy but shows some improvement versus prior years: operating cash flow was around -$100M in 2023 and -$99.7M in 2024, compared with about -$144.0M in TTM (Trailing-Twelve-Months). Free cash flow is also negative (about -$144.7M TTM), implying ongoing reliance on external funding. A positive note is that free cash flow has been roughly in line with reported losses (free cash flow to net income near 1x historically), suggesting limited non-cash distortion, but the overall cash trajectory still reflects a high-burn development-stage profile.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.69M	0.00	-3.49M	-8.96M	0.00	0.00
EBITDA	-1.12B	-117.66M	-114.37M	-83.13M	-67.58M	-42.76M
Net Income	-2.45B	-116.91M	-117.86M	-92.09M	-68.90M	-43.34M
Balance Sheet
Total Assets	176.24M	142.89M	209.83M	299.37M	242.59M	75.91M
Cash, Cash Equivalents and Short-Term Investments	170.46M	91.93M	137.18M	230.25M	207.47M	48.54M
Total Debt	3.06M	31.83M	35.66M	38.91M	18.01M	18.29M
Total Liabilities	2.40B	46.23M	59.10M	48.76M	26.33M	27.64M
Stockholders Equity	-2.23B	96.66M	150.72M	250.61M	216.26M	48.27M
Cash Flow
Free Cash Flow	-144.67M	-99.89M	-101.36M	-93.61M	-73.04M	-40.45M
Operating Cash Flow	-143.97M	-99.66M	-100.29M	-85.14M	-69.14M	-36.29M
Investing Cash Flow	100.00K	96.86M	71.01M	-94.09M	-91.65M	-4.16M
Financing Cash Flow	249.29M	53.39M	2.94M	117.14M	232.91M	82.53M

Vor Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.55
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VOR, the sentiment is Positive. The current price of 13.55 is above the 20-day moving average (MA) of 13.43, below the 50-day MA of 13.67, and below the 200-day MA of 22.36, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 60.74 is Neutral, neither overbought nor oversold. The STOCH value of 59.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VOR.

Vor Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDTX	59 Neutral	$128.76M	6.34	19.23%	―	―	―
AVIR	58 Neutral	$359.38M	-2.67	-37.98%	―	―	14.33%
KYTX	54 Neutral	$438.75M	-2.18	-70.82%	―	―	-21.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VOR	50 Neutral	$548.06M	-0.03	―	―	―	-1072.48%
CRBU	47 Neutral	$151.42M	-1.04	-74.28%	―	-19.00%	-2.72%
CDXS	42 Neutral	$105.68M	-1.57	-114.26%	―	-17.87%	14.42%

Vor Biopharma Corporate Events

Vor Biopharma to Highlight Telitacicept at JPM Conference

Vor Biopharma announced that it will present and host one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026, where it is highlighting telitacicept as a leading dual BAFF/APRIL inhibitor for B cell–mediated autoimmune diseases. The company emphasized that telitacicept already has an established commercial footprint and broad clinical data package in China through partner RemeGen across several autoimmune conditions, a favorable and predictable safety profile observed in about 1,800 clinical trial participants and tens of thousands of treated patients, and robust efficacy signals in generalized myasthenia gravis, while outlining a global development plan that includes a Phase 3 trial in generalized myasthenia gravis with topline data expected in the first half of 2027 and a Phase 3 trial in Sjögren’s disease planned to start in the first half of 2026, supported by approximately $450 million in cash and investments as of December 2025, which the company says provides runway into mid-2028 to fund these key milestones.

The most recent analyst rating on (VOR) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.

Vor Biopharma CDO Departs, Transition Support Planned

On December 31, 2025, Vor Biopharma Inc. entered into a separation agreement with its Chief Development Officer, Dr. Qing Zuraw, following her decision to pursue other opportunities, with her employment ending the same day and severance benefits provided in line with the terms of her 2025 employment agreement and subsequent amendment. The agreement includes a general release of claims, a 12‑month non‑compete, and standard non‑disparagement and confidentiality provisions, and the company expects to engage Dr. Zuraw as a consultant to support the transition during the first quarter of 2026, signaling an effort to maintain continuity in its development operations despite the leadership change.

The most recent analyst rating on (VOR) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.

Vor Biopharma strengthens board following $150M private placement

On December 15, 2025, Vor Bio entered into a securities purchase agreement for a $150 million private placement of 13,876,032 common shares at $10.81 each to a group of institutional and accredited healthcare specialist investors, including RA Capital Management and Forbion, without using a placement agent. The company plans to use the proceeds to fund the clinical development of its lead asset telitacicept, including an ongoing global Phase 3 trial in myasthenia gravis and a planned global Phase 3 trial in primary Sjögren’s disease, and for general corporate purposes, while concurrently granting investors registration rights for resale of the shares and allowing Forbion to appoint one director to Vor Bio’s board. On December 17, 2025, board member Sarah Reed resigned without a dispute, and on December 18, 2025, Vor Bio appointed RA Capital’s Andrew Levin as an independent Class II director and Forbion’s Wouter Joustra as an independent Class III director, moves that deepen the company’s ties with major life sciences investors and bring additional venture and capital markets expertise to its board as it advances late-stage autoimmune programs.

The most recent analyst rating on (VOR) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.

Vor Biopharma Approves Stock Option Repricing Plan

On December 5, 2025, Vor Biopharma‘s board approved a stock option repricing, reducing the exercise price of certain options to $8.18 per share to align with the market value on that date. This decision aims to retain and motivate employees by making their options more attractive without incurring additional equity or cash costs, impacting approximately 5.2 million shares. The repricing includes options held by key executives, such as CEO Jean-Paul Kress, and involves a retention period until December 5, 2027, or other specified conditions. Additionally, CFO Sandy Mahatme’s restricted stock units were replaced with an option to purchase 1,388,274 shares, with similar repricing terms.

The most recent analyst rating on (VOR) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.

Vor Biopharma Announces $93.7 Million Public Offering

On November 10, 2025, Vor Biopharma Inc. announced an underwriting agreement for a public offering of 10 million shares of common stock at $10 per share, expected to raise approximately $93.7 million. The proceeds will be used to advance clinical development of telitacicept, including a Phase 3 trial for primary Sjögren’s Disease, and support manufacturing and pre-commercialization activities. This financial move aims to sustain the company’s operations and capital expenditures into the second quarter of 2027, potentially strengthening its position in the biotechnology sector.

The most recent analyst rating on (VOR) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.